In both the B16F10 melanoma and E.G7-OVA lymphoma model, TDLN-targeting nanoparticle (NP)-conjugate vaccines induced substantially stronger local and systemic cytotoxic CD8+ T-cell responses when compared to non-TDLN-targeting vaccination, leading to enhanced tumor regression and host survival (237). The gene discussed is CD8A; the disease is melanoma.